Atriva Therapeutics takes part in four conferences in the upcoming months

  • 2 min read

Atriva Therapeutics takes part in four conferences in the upcoming months

 TĂĽbingen (Germany), September 4, 2019 – Atriva Therapeutics GmbH, a biopharma­ceutical company pioneering the development of host-targeting antiviral therapies, today announced its participation in four upcoming partnering conferences worldwide.

Dr. Rainer Lichtenberger, CEO of Atriva, will represent the Company and will be available for networking and one-on-one meetings at the following events:

12th Annual International Partnering Conference BioPharm America
September 11th â€“ 12th, 2019, Boston Convention & Exhibition Center, Boston, MA, USA
Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation on September 12th, 3:00 – 3:10 pm EST.
ebdgroup.knect365.com/biopharm-america

19th Annual Biotech in Europe Forum (Sachs Conference)
September 25th â€“ 26th, 2019, Congress Center Basel, Switzerland
Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation on September 25th, 12:20 CET. Dr. Lichtenberger will also participate in the â€śVaccines & Infectious Disease Panel” on September 25th, 17:05 CET.
www.sachsforum.com/bef19-about.html

25th Annual International Partnering Conference BIO-Europe®
November 11th â€“ 13th, 2019, Hamburg Messe, Hamburg, Germany
Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation.
ebdgroup.knect365.com/bioeurope

6th China Healthcare Summit 2019
November 18th â€“ 20th, 2019, Jing An Shangri-La, Shanghai, China
www.biocentury.com/conferences/china-healthcare-summit-2019

About Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies setup by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different respiratory viral infections. The lead product ATR-002 is a first-in-class host-targeting agent, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. ATR-002 is under clinical development in a Phase I trial to evaluate safety and tolerability in healthy subjects. The Company owns seven broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2039. Atriva Therapeutics is located in TĂĽbingen and Frankfurt, Germany.

For further information, please visit www.atriva-therapeutics.com or see our LinkedIn profile  Atriva Therapeutics GmbH.

Contact:
Atriva Therapeutics GmbH

Dr. Rainer Lichtenberger, CEO
phone: +49 6196 56 11 698
mobile: +49 151 7443 3175
lichtenberger@atriva-therapeutics.com

Media and Investor Relations:
MC Services AG
Eva Bauer / Raimund Gabriel
phone: +49 89 210 228 80
atriva-therapeutics@mc-services.eu